tradingkey.logo
tradingkey.logo
Search

OPKO Health Inc

OPK
Add to Watchlist
1.240USD
+0.030+2.48%
Close 04/17, 16:00ETQuotes delayed by 15 min
941.24MMarket Cap
LossP/E TTM

OPKO Health Inc

1.240
+0.030+2.48%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of OPKO Health Inc

Currency: USD Updated: 2026-04-17

Key Insights

OPKO Health Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 40 out of 75 in the Healthcare Providers & Services industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 3.40.In the medium term, the stock price is expected to trend down.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

OPKO Health Inc's Score

Industry at a Glance

Industry Ranking
40 / 75
Overall Ranking
185 / 4524
Industry
Healthcare Providers & Services

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

OPKO Health Inc Highlights

StrengthsRisks
OPKO Health, Inc. is a multinational biopharmaceutical and diagnostics company. The Company’s segments include pharmaceutical and diagnostics. The pharmaceutical segment consists of the pharmaceutical operations it operates in Chile, Mexico, Ireland, Israel, Spain, Ecuador, France, the United States, and its global pharmaceutical research and development operations. The diagnostics segment primarily consists of clinical laboratory operations through BioReference and its point-of-care operations. Its pharmaceutical business features Somatrogon (hGH-CTP), a once-weekly human growth hormone injection, and it is marketed under the brand name NGENLA. The Company, through its pharmaceutical division, manufactures and sells Rayaldee, a United States Food and Drug Administration (FDA) approved treatment for secondary hyperparathyroidism (SHPT) in adults with stage 3 or 4 chronic kidney disease (CKD) and vitamin D insufficiency.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 606.88M.
Overvalued
The company’s latest PE is -4.13, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 203.58M shares, decreasing 16.68% quarter-over-quarter.
Held by PRFDX
Star Investor PRFDX holds 44.46K shares of this stock.

Analyst Rating

Based on 7 analysts
Buy
Current Rating
3.400
Target Price
+188.14%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-04-17

The current financial score of OPKO Health Inc is 6.97, ranking 47 out of 75 in the Healthcare Providers & Services industry. Its financial status is robust, and its operating efficiency is average. Its latest quarterly revenue reached 148.45M, representing a year-over-year decrease of 19.16%, while its net profit experienced a year-over-year decrease of 322.83%.

Score

Industry at a Glance

Previous score
6.97
Change
0

Financials

8.92

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

7.31

Operational Efficiency

6.13

Growth Potential

5.38

Shareholder Returns

7.12

OPKO Health Inc's Company Valuation

Currency: USD Updated: 2026-04-17

The current valuation score of OPKO Health Inc is 8.03, ranking 17 out of 75 in the Healthcare Providers & Services industry. Its current P/E ratio is -4.13, which is -43.76% below the recent high of -2.32 and -552.95% above the recent low of -26.95.

Score

Industry at a Glance

Previous score
8.03
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 40/75
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-04-17

The current earnings forecast score of OPKO Health Inc is 8.00, ranking 29 out of 75 in the Healthcare Providers & Services industry. The average price target is 3.00, with a high of 8.50 and a low of 1.60.

Score

Industry at a Glance

Previous score
8.00
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 7 analysts
Buy
Current Rating
3.400
Target Price
+188.14%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

64
Total
4
Median
6
Average
Company name
Ratings
Analysts
OPKO Health Inc
OPK
7
Apple Inc
AAPL
48
Ge Vernova Inc
GEV
36
Tapestry Inc
TPR
24
Verisk Analytics Inc
VRSK
20
Avantor Inc
AVTR
20
1
2
3
...
13

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-04-17

The current price momentum score of OPKO Health Inc is 7.87, ranking 50 out of 75 in the Healthcare Providers & Services industry. Currently, the stock price is trading between the resistance level at 1.29 and the support level at 1.14, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.42
Change
1.45

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(1)
Neutral(2)
Buy(2)
Indicators
Value
Direction
MACD(12,26,9)
0.021
Neutral
RSI(14)
61.645
Neutral
STOCH(KDJ)(9,3,3)
82.743
Buy
ATR(14)
0.040
High Vlolatility
CCI(14)
183.720
Buy
Williams %R
6.452
Overbought
TRIX(12,20)
0.019
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(2)
Neutral(0)
Buy(4)
Indicators
Value
Direction
MA5
1.194
Buy
MA10
1.184
Buy
MA20
1.161
Buy
MA50
1.183
Buy
MA100
1.251
Sell
MA200
1.324
Sell

Institutional Confidence

Currency: USD Updated: 2026-04-17

The current institutional shareholding score of OPKO Health Inc is 3.00, ranking 56 out of 75 in the Healthcare Providers & Services industry. The latest institutional shareholding proportion is 26.82%, representing a quarter-over-quarter increase of 5.15%. The largest institutional shareholder is The Vanguard, holding a total of 32.35M shares, representing 4.26% of shares outstanding, with 14.87% increase in holdings.

Score

Industry at a Glance

Previous score
3.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
Frost Gamma Investments Trust
222.46M
+0.98%
Rubric Capital Management LP
47.79M
--
Holbrook (Bruce C)
40.38M
--
Hsiao (Jane H)
33.13M
--
The Vanguard Group, Inc.
Star Investors
32.35M
-13.64%
BlackRock Institutional Trust Company, N.A.
31.23M
+5.20%
Frost Group, L.L.C.
30.13M
--
GJN 2021 Trust
19.91M
--
EGN 2021 Trust
19.91M
--
Geode Capital Management, L.L.C.
11.06M
+0.62%
1
2

Risk Assessment

Currency: USD Updated: 2026-04-17

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Providers & Services domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of OPKO Health Inc is 6.17, ranking 30 out of 75 in the Healthcare Providers & Services industry. The company's beta value is 1.51. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.

Score

Industry at a Glance

Previous score
6.17
Change
0
Beta vs S&P 500 index
1.51
VaR
+4.88%
240-Day Maximum Drawdown
+30.38%
240-Day Volatility
+44.77%

Return

Best Daily Return
60 days
+6.98%
120 days
+6.98%
5 years
+20.08%
Worst Daily Return
60 days
-4.27%
120 days
-6.85%
5 years
-39.55%
Sharpe Ratio
60 days
-0.27
120 days
-1.03
5 years
-0.13

Risk Assessment

Maximum Drawdown
240 days
+30.38%
3 years
+60.12%
5 years
+83.19%
Return-to-Drawdown Ratio
240 days
-0.34
3 years
-0.08
5 years
-0.16
Skewness
240 days
+0.32
3 years
-2.14
5 years
-0.81

Volatility

Realised Volatility
240 days
+44.77%
5 years
+61.36%
Standardised True Range
240 days
+4.14%
5 years
+7.95%
Downside Risk-Adjusted Return
120 days
-176.19%
240 days
-176.19%
Maximum Daily Upside Volatility
60 days
+25.67%
Maximum Daily Downside Volatility
60 days
+23.84%

Liquidity

Average Turnover Rate
60 days
+0.42%
120 days
+0.47%
5 years
--
Turnover Deviation
20 days
-50.57%
60 days
-39.63%
120 days
-32.94%

Peer Comparison

Healthcare Providers & Services
OPKO Health Inc
OPKO Health Inc
OPK
7.04 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Encompass Health Corp
Encompass Health Corp
EHC
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Cigna Group
Cigna Group
CI
8.58 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Natera Inc
Natera Inc
NTRA
8.51 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Alignment Healthcare Inc
Alignment Healthcare Inc
ALHC
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Labcorp Holdings Inc
Labcorp Holdings Inc
LH
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
KeyAI